SGLT2 inhibitor dapagliflozin consistently reduced blood pressure, body weight and albuminuria, independently of baseline renal function.
In a large group of well-controlled TECOS trial diabetes patients ≥75 years, DPP4 inhibitor sitagliptin did not increase the risk of serious hypoglycaemia and was neutral with respect to CV outcomes.
The clinical phase III trial EMPEROR HF is initiated and evaluates CV death and hospitalisation for heart failure with empagliflozin in ~7 000 HFrEF and HFpEF patients with or without diabetes
ACC 2017 AF patients starting digoxin treatment showed increased mortality, especially in the first 6 months, irrespective of the coexistence of HF, and digoxin concentrations >1.2 ng/ml should be avoided.
ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.
ACC 2017 Paroxysmal AF was associated with a higher risk of HF hospitalisation and stroke, while new-onset AF was associated with a higher risk of HF hospitalisation, death and stroke.
In the phase III RELAX-AHF-2 study, the primary endpoints reduced CV death or worsening HF were not met when RLX030 was given op top of standard therapy in patients with acute HF.
In ODYSSEY trials, LDL-lowering and adverse events were not different between patients with and without antidrug antibodies against PCSK9 antibody alirocumab.
ACC 2017 Dr. Robert Giugliano presented the EBBINGHAUS trial, testing the cognitive function of almost 2000 patients from the FOURIER trial. There was no difference between the groups with the PCSK9-inhibitor and placebo, even at very low cholesterol levels.
ACC 2017 In addition to its cardiovascular benefits, sacubitril/valsartan also reduces HbA1c levels, compared to enalapril.
ACC 2017 In a large real-world study, treatment with SGLT-2 inhibitors versus other glucose-lowering drugs was associated with significant reductions in HF hospitalisation and all-cause death in diabetic patients.
ACC 2017 In non-cardiac surgery patients, a peak postoperative hsTnT measurement ≥ 20 ng/L and an absolute change of ≥ 5 ng/L was significantly associated with 30-day mortality.